Delivering revolutionary treatments to the patients who need them most.
We believe that the best way to test cancer therapies is on the cancer itself. Our lab uses live tumour slices to analyse therapeutic efficacy, providing patient-specific, clinically relevant data to help get treatments into clinic. We can work across tumour types and therapy modalities to develop a bespoke panel of tests best suited to each therapy.
At AEONOX Pathology we believe that the best way of testing drugs for cancer, is to test them on the cancer itself. We want to give clinicians and drug companies data which truly informs how well patients will respond to treatment, improving cancer care from lab bench to clinic.
Our personalised approach uses the patient’s tumour slices to work out which treatments will benefit them most. Alongside current therapies, we can use our platform to gather representative data for drug companies, helping them to launch smarter, safer products. Our platform is compatible with a wide range of tumour and treatment types, providing fast, comprehensive analysis.
Superior platform: Cellular heterogeneity, physicochemical properties, immune microenvironment all preserved
Rapid analysis: Overcome barriers created by complex generation and treatment of mouse models
Immunotherapy development: Novel microscopy techniques allow analysis of immunotherapy efficacy including tissue penetration, (motility and activation)
Bespoke data: Our testing can be tailored to suit the specific target and challenges faced in therapeutic development, helping to tackle potential barriers early in development
Alice is a PhD student in the O’Neill lab working on perfusion culture of tumour slices. She holds a first-class undergraduate degree in Biomedical Sciences from Oxford with prior experience in haematology and immunology research. She has worked as a scientific consultant for Kuperstein Kapital and a commercial journalist for InvIOs Bio.
Professor O’Neill is head of the Cell and Molecular signalling lab in Oxford University’s Department of Oncology. As an academic he has made seminal discoveries in cancer biology and has been involved a number of national initiatives in translational oncology with clinical colleagues. He is also the founder and CSO of Epicombi.ai who are using artificial intelligence and machine learning to develop novel therapeutics.
IF YOU WOULD LIKE TO KNOW MORE ABOUT OUR SERVICES, PLEASE LEAVE YOUR DETAILS BELOW.
We always welcome feedback so we can continually improve our offering. If you would like more information or to discuss our technology please send us your contact details.